DOCSLIB.ORG

FARAD Digest Extralabel Use of Nonsteroidal Anti-Inflammatory Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FARAD Digest Extralabel Use of Nonsteroidal Anti-Inflammatory Drugs FARAD Digest Extralabel use of nonsteroidal anti-inflammatory drugs Paul Damian, PhD, MPH; Arthur L. Craigmill, PhD; Jim E. Riviere, DVM, PhD I n a recent survey of food animal veterinarians, it Table 1-FARAO recommendedwithdrawal intervals was found that 93%reported using nonsteroidal anti- MIlk Melt inflammatory dmgs (NSAlD), and almost60% reported y.~,,-;-""~- using thesedrugs more than once a week.1 Dairy prac- Dr-. --- 0 IIt8V8I(hi 1ItMWIlldi titioners use NSAID more frequently than beef practi- Aspirin All food AftI11III1 doslges 24 1 Inknl" tioners, and flunixin meglumineis usedmore frequently DipyIOnI Not IPIIrOV8din than aspirin, phenylbutazone,or dipyrone. At this time, food animals no commonly used NSAID has been approved for use K8IDprofIn Caull 3.3IRA, IVor 1M, 24 7 q 24 h, for up to in food animals in the United States.The purpose of 3 days this article is to provide practitionerswith recommended GOlts 3.3malkg, IV or 1M, 24 7 milk and meat withdrawal intervals (WDI) for some q 24h, for up to 3 days uses of NSAID. Sheep 3.3mglkg. IV or 1M, 24 7 q 24 h. for up to 3 days Aspirin Flunixin Cattle 1.1-2.2mg/kg, IV or 72 10 Aspirin (acetylsalicylicacid) is commonly used in megluminl 1M,q 24h, for food animals.Available over-the-counter, it is most com- 3to5dlyl Swine 2 mg/kg.1M NA 15 monly administeredas 60- or 240..graintablets (1 grain = PlllnylbulllOnl CaIIIl 6 g/animal.IV or 1M. 12 65 mg). Aspirin formulations havenot beenapproved by 4-t g/anlmll,IV or 131 21 the FDA-Center for Veterinary Medicine (FDA-CVM); 1M,toa_d by up to 2 g/lnlml' however,the agencyconsiders use of aspirin to be of low daily regulatoryconcern. Under this policy, the FDA-CVM as- sumesthat veterinariansknow how to usethe drug prop- -Toc-.tw ~. divideby U erly and that the drug doesnot presenta substantialfood NA."~, safetyissue; therefore, formal drug approvalis not neces- sary.However, it also meansthat uniform WDI recom- the Dec 6, 1995 GYM Updateand include a lack of data mendations have not been establishedfor commercial indicating that dipyrone is safeand effective as well as aspirin products, although someproduct labelsdo con- lack of pharmacokinetic and residue infonnation that tain warnings againstuse in lactating dairy animals.De- can be used to establish a WDI. In addition, dipyrone spite the fact that aspirin is of low regulatory concern, has been associatedwith toxic effects in human be- some epidemiologicdata suggesta link betweensalicy- ings, including bone-marrow toxicosis, agranulocytic lates and Reyessyndrome in children with chickenpox anemia, and teratogenicity. or influenza} For this reason,FARAD recommends mini- mum meat and milk WDI of 24 hours for typical usesof Ketoprofen aspirin in food animals. There are few published residue or pharmacoki- netic data for ketoprofen. Available data in cattle indi- Dipyrone catea short terminal half-life of 30 minutes and a small Extralabel use of dipyrone in food animals is spe- volume of distribution (0.2 Ukg [0.09 IJ1b]). Milk cifically prohibited by the FDA-CVM; therefore,FARAD concentrations following IV administration at the rate does not offer extralabel WDI recommendations for of 3.3 mg/kg (1.5 mg/lb) of body weight to dairy cows this drug. Reasonsfor this prohibition are describedin werealways less than the limit of quantitation(27 ng/ml). Results in lactating goats also indicated a short half- Prom the Food Animal Residue Avoidance Databank (FARAD), Environmental Toxicology Extension, College or AgricultUral and life (20 minutes) and a small volume of distribution Environmental Sciences, University of CaUfomia, Davis, CA 95616- (0.23 Ukg [0.10 IJ1b]), suggesting limited distribu- 8.588 (Damian, Craigmill), and FARAD, Cutaneous Pharmacology tion in tissue. Ketoprofen was not detected in milk and Toxicology Center, College of Veterinary Medicine, North from goats treated with a single IV bolus at 2.2 mg/kg Carolina State University, Raleigh,NC 27606 (Riviere). (1 mg/ib). In France,ketoprofen is approved for use in Referencesto studies mentioned in this reP;Ortand references for FARAD determinations are available on written request. cattle, and recommendedmeat and milk WDI for this laU/8~-r,umxln vetennery proaucts approvedtor use in food animals in foreign countries Table 3-Pheny1butazone veterinary products approved .. ... for use in food animals in foreign countries ~ 0 v.-:".-11""'.'I~I II1II..I~ ~ ... ~ ..~~ ..~~ flllland c.1d8 2.2~ IV,q 24h,:' 7 ~ .. ~ .41 for up to 5 dlY' SwfIz8ftIIId CIaII W FrInc. c.1d8 2 ~, W~ 1M . '. .,..,... IIow 1a 12 WI8 2 nII/ke.1M NA . IV or 1M ~ c.1d8 2.2n'IOI'ko. IV. 1M. 72 I CaIYII 1-2 8/1'*nIUM 12 SwIne ,~ 8/1""1, 1M 12 q24h fr8IC8 c... 48/111in11.1V~. 21 1M, on die firII s.. TIbII1 for kIY. diY, 2 8/lntmll on Sla.qlJ8ntdlyl CMs 2 g/1IimII,IV or NA 21 drug given IV or 1M at 3.3 mglkg, every 24 hours, for 1M, on dIe 11m 3 days, are 4 and 0 days, respectively.On the basis of dIY, 1 g/lninli on IU.UI" dIYI this information, FARAD recommendsmeat and milk SwinI 2~ ~lnimlllV or NA Z1 WDI of 7 days and 24 hours, respectively, for use of 1M,q 24h ketoprofen in cattle, sheep,or goatsat dosagesof up to '-',., C6 W 1Iow . 11 lVorN 3.3 mg/kg, every 24 hours, for up to 3 days (Table 1). CaIve8 1~g/II8lIM NA 12 SMI8 1.W "IM NA 12 Flunlxln Mevlumine In the United States,flunixin meglumine is labeled "'TI~I_W for use in horses only. Only limited pharmacokinetic I and residue data are available in food animals. In 1 c nance dosageof 2..5to 14.0 mg/kg (1.1 to 6.4 mg/lb), study, 1 cow was given 2.2 mg of flunixin meglumin~g t every 24 or 48 hours. The potential for residues in (1 mg/lb), IV; twice, 12 hours apart. Concentrations of 1 treated animals is high becauseof its long elimination flunixin meglumine in milk 24 hours after treatment i half-life in cattle. Plasmaelimination half-lives rang- were similar to concenn-ationsin milk from untreated ~ing from 30 to 80 hours havebeen reponed, with about control animals. In a radiolabel study in which cows f 40 hours being most common. Phenylbutazoneis also received2.2 mgIkg, IV;background concentrations were ~excreted in milk. In cows. given a loading dose of reachedin milk by 72 hours. In a multiple dosing study, f 24 IngI1cg (11 mgI1b)followed by 12 mgIkg (5.5 mgAb), lactating cows received 1.1 mg/kg (0.5 mg/lb), every 8 t every 24 hours, milk residues were detected until 82 hours. Residueswere not detected in oillk at any sam- d hours after the last dose. In another study, milk resi- piing time at a detection limit of 50 ng/ml. The termi- Sdues declined to the detection limit (0.05 ~g/ml) nal elimination half-life in sheep and cattle has been cJ5 days after cows received 2.5 g, PO, every 12 hours, reported as ranging from 3 to 9 hours. In the only £ daily, for 5 days.Only 1 tissueresidue study for PBZ in tissue residue study available,liver and kidney samples r food animals could be located. In cows given a single from cattle given 2.2 mg/kg. IV; had residues of about a IV injection of 7.5 mg/kg (3.4 mg/lb; 3.75 g/animal), 0.05 ~g/mI 5 days after treatment. dabout 14 dayswere required for muscle and liver resi- Flunixin meglumine is approved for use in food Sdues to decline to < 0.1 ~g/g. The half-life of PBZ was animals in several other countries, including England. 56 days in liver and muscle. France. Switzerland, and Germany (Table 2). For the c SeveralPBZ products havebeen approved for use in same dose in cattle. foreign WDI recommendations ( cattle and swine in Germany;Switzerland, and France vary widely. For catde given the typical dosageof 1.1 I (Table 3). Meat WDI range from 3 to 21 days,wh~ to 2.2 mg/kg (0.5 to 1.0 mg/ib), IV or 1M, every 2~ J milk WDI rangefrom 48 to 120 hours. On the basisof hours, for 3 to .5days, FARAD recommendsuse of the j residueand pharmacoktneticdata mentioned,as well as milk WDI specified by the Swiss product (72 hours) , foreign withdrawal time recommendations,FARAD rec- and the meatWDI specified by the French product (10 J ommendscattle meat and Inilk WDI of 12 days and 96 days). For swine given up to 2 mw'kg (0.9 mg/ib), 1M, hours, respectively;for a single doseof up to 6g of PBZJ FARAD recommends use of the French meat WDI of animal. For a multiple doseregimen in which a loading IS days (Table 1). doseof 4 to 6 g/animal is given IV or 1M followed by up to 2 g daily,FARAD recommends meat and Inilk WDI of PhenylbUt8zone 21 daysand 120 hours, respectively(Table 1). Although not approved for use in food animals in theUnited States,phenylbutazone (PBZ) is widely used Reference. In cattle. Two types of treatment are common: a single I. KopchaM, KaneeneJB. SheaME, et II. Use of nonsteroi- lose of 4 to 6 g/animal, 1M or Iv; or a multiple dose dal Inti-inflammatory dnap In food animal practice. J Alii Vet regimenconsisting of a loading dose of 10 to 25 mg/kg Med &soc 1992;201:1868-1872. :4.5 to 11.0 mg/ib), 1M or Iv; followed by a mainte- 2.
Load more

Recommended publications
  • Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep
    animals Article Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep Shashwati Mathurkar 1,*, Preet Singh 2 ID , Kavitha Kongara 2 and Paul Chambers 2 1 1B, He Awa Crescent, Waikanae 5036, New Zealand 2 School of Veterinary Sciences, College of Sciences, Massey University, Palmerston North 4474, New Zealand; [email protected] (P.S.); [email protected] (K.K.); [email protected] (P.C.) * Correspondence: [email protected]; Tel.: +64-221-678-035 Received: 13 June 2018; Accepted: 16 July 2018; Published: 18 July 2018 Simple Summary: Scarcity of non-steroidal anti-inflammatory drugs (NSAID) to minimise the pain in sheep instigated the current study. The aim of this study was to know the pharmacokinetic parameters of salicylic acid in New Zealand sheep after administration of multiple intravenous and oral doses of sodium salicylate (sodium salt of salicylic acid). Results of the study suggest that the half-life of the drug was shorter and clearance was faster after intravenous administration as compared to that of the oral administration. The minimum effective concentration required to produce analgesia in humans (16.8 µL) was achieved in sheep for about 0.17 h in the current study after intravenous administration of 100 and 200 mg/kg body weight of sodium salicylate. However, oral administration of these doses failed to achieve the minimum effective concentration as mentioned above. This study is of significance as it adds valuable information on pharmacokinetics and its variation due to breed, species, age, gender and environmental conditions.
    [Show full text]
  • Flunixin, Extension to Horses
    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/744/00- FINAL June 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS FLUNIXIN (Extension to horses) SUMMARY REPORT (2) 1. Flunixin is a non-steroidal anti-inflammatory drug (NSAID), and a non-narcotic analgesic with antipyretic activities. In veterinary medicine, it is used with meglumine as solubilizer as flunixin meglumine. Flunixin meglumine is used in the alleviation of inflammation and pain associated with musculo-skeletal disorders and colic in horses; the control of acute inflammation associated with infectious diseases in cattle and as an aid in the treatment of mastitis metritis agalactia syndrome (MMA) in sows. A dose of 2.2 mg/kg bw by the intravenous route once a day for up to 3 days is indicated for bovines, whilst 2.2 mg/kg bw intramuscularly (up to 2 injections, 12 hours apart) is recommended for sows affected by MMA syndrome. Flunixin meglumine is also used in veterinary medicine in combination with oxytetracycline for the treatment of bovine pneumonia at a dose of 2 mg/kg bw (once a day for 3 to 5 days by the intravenous or the intramuscular routes). The Committee for Veterinary Medicinal Products (CVMP) previously retained an ADI of 6 µg/kg bw (i.e. 360 µg/person) for flunixin, by applying a safety factor of 100 to the NOEL of 0.6 mg/kg bw/day which was established in a 90-day repeated dose gavage study in the dog. Flunixin is currently included in Annex I of Council Regulation (EEC) No 2377/90 in accordance with the following table: Pharmacologically Marker Animal MRLs Target tissue Other active substance(s) residue species provisions Flunixin Flunixin Bovine 20 µg/kg Muscle 30 µg/kg Fat 300 µg/kg Liver 100 µg/kg Kidney 5-Hydroxy Bovine 40 µg/kg Milk flunixin Flunixin Porcine 50 µg/kg Muscle 10 µg/kg Skin + fat 200 µg/kg Liver 30 µg/kg Kidney An application has now been received for the extention of the MRLs for flunixin to edible tissues of horses.
    [Show full text]
  • Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic
    Sys Rev Pharm 2020; 11(5): 464 468 A multifaceted review journal in the field of pharmacy E-ISSN 0976-2779 P-ISSN 0975-8453 Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic Agus Purnomo1, Arya Pradana Wicaksono2, Dodit Hendrawan2, Muhammad Thohawi Elziyad Purnama3* 1Department of Veterinary Surgery and Radiology, Faculty of Veterinary Medicine, Universitas Gadjah Mada, DI Yogyakarta, 55281, Indonesia 2Postgraduate Studies, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia 3Department of Veterinary Anatomy, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia *Corresponding author E-mail: [email protected] Article History: Submitted: 26.02.2020 Revised: 16.04.2020 Accepted: 21.05.2020 ABSTRACT This study aimed to evaluate the efficacy of flunixin, ketoprofen and multiple range test. The results showed a significant alleviation in all phenylbutazone on serum biochemistry, plasma catecholamines and observed variables on Day 13, although the use of various NSAIDs serum cortisol in Delman horses with mild colic. During the study showed no significant difference. period, 32 horses were evaluated due to mild colic. Flunixin, Keywords: serum biochemical, catecholamine, cortisol, colic, NSAIDs ketoprofen, and phenylbutazone were administered intravenously at Correspondence: the recommended dose rates of 1.0; 2.2 and 4.4 mg/kg, respectively. Muhammad Thohawi Elziyad Purnama Administration of the NSAIDs commenced on Day 1 and continued Department of Veterinary Anatomy, Faculty of Veterinary Medicine, every 12 h for 12 days. Blood samples collected between days 2, 5, 9 Universitas Airlangga, Surabaya, 60115, Indonesia and 13 to evaluate AST, ALP, GGT, creatinine, urea, epinephrine, E-mail: [email protected] norepinephrine, and cortisol level.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANALYSIS IN MILK BY QUECHERS AND LC-MS: LOW AND HIGH RESOLUTION DETECTION AND CONFIRMATION APPROACHES A. Rúbies1, L. Guo2, I. Beguiristain1, F. Centrich1, M. Granados2 1. Laboratori Agència de Salut Pública de Barcelona, 2. Departament de Química Analítica - Universitat de Barcelona. * INTRODUCTION NON-STEROIDAL ANTI-INFLAMATORY DRUGS (NSAIDs) Non-steroidal anti-inflammatory drugs (NSAIDs) are used as anti-inflammatory, analgesic and OXICAMS ANTHRANILIC ACID DERIVATIVES ACETIC ACID antipyretic drugs in medicine and veterinary. Their action mechanism is based on the blocking of PROPIONIC ACID DERIVATIVES DERIVATIVES the biosynthesis of prostaglandins. NSAIDs are highly effective and extensively used, but they have some adverse side effects, such as hepatotoxicity, renal disorders or allergic reactions. In the European Union, to assure food safety and protect consumers, maximum residue limits have been established for some authorised NSAIDs in food products. Therefore, high throughput and reliable analytical methodology is required for the effective control of NSAIDs in food from animal Flufenamic acid origin. Liquid chromatography (LC) coupled to mass spectrometry (MS) is currently the technique of choice in confirmatory analysis of NSAIDs residues. We present a new method for the determination of representative NSAIDs in milk based on QuEChERS methodology, LC-MS/MS and UHPLC-HRMS. Meloxicam Ketoprofen Diclofenac EU Maximum Residue Limits (MRLs) Recommended NSAIDs concentrations for NSAIDs in milk.
    [Show full text]
  • Nonsteroidal Anti-Inflammatory Agents Differ in Their Ability to Suppress
    Oncogene (2004) 23, 9247–9258 & 2004 Nature Publishing Group All rights reserved 0950-9232/04 $30.00 www.nature.com/onc Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-jB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation Yasunari Takada1, Anjana Bhardwaj1, Pravin Potdar1 and Bharat B Aggarwal*,1 1Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Box 143, 1515 Holcombe Boulevard, Houston, TX 77030, USA Nonsteroidal anti-inflammatory drugs (NSAIDs) such as Introduction aspirin have been shown to suppress transcription factor NF-jB, which controls the expression of genes such as Owing to its analgesic and anti-inflammatory effects, cyclooxygenase (COX)-2 and cyclin D1, leading to aspirin (acetylsalicylic acid), first synthesized in 1897, inhibition of proliferation of tumor cells. There is no was approved for the treatment of rheumatoid arthritis systematic study as to how these drugs differ in their ability in 1899 (Botting, 1999). Since then several other to suppress NF-jB activation and NF-jB-regulated gene nonsteroidal anti-inflammatory drugs (NSAIDs) have expression or cell proliferation. In the present study, we been synthesized and approved for human use. The anti- investigated the effect of almost a dozen different commonly inflammatory and analgesic effects of NSAIDs have used NSAIDs on tumor necrosis factor (TNF)-induced NF- been shown to be due to their ability to inhibit the jB activation and NF-jB-regulated gene products, and on enzymatic activity of cyclooxygenases (COXs), which cell proliferation. Dexamethasone, an anti-inflammatory convert arachidonic acid to prostaglandins (PGs) (Vane, steroid, was included for comparison with NSAIDs.
    [Show full text]
  • Topical NSAID for Osteoarthritis Safe and Effective (Print)
    The Horse: Study: Topical NSAID for Osteoarthritis Safe and Effective (print) Study: Topical NSAID for Osteoarthritis Safe and Effective by: Stacey Oke, DVM, MSc February 26 2009 Article # 13686 Move over, Bute. In a new independent study, researchers at Colorado State University's Gail Holmes Equine Orthopaedic Research Center concluded that diclofenac liposomal cream (1% diclofenac sodium, trade name Surpass) is safer and more effective than phenylbutazone for treating discomfort associated with osteoarthritis in horses. Phenylbutazone, commonly known as "Bute," is a non-steroidal anti-inflammatory (NSAID) drug administered systemically (i.e., intravenously or orally) to help control the pain and inflammation caused by osteoarthritis in horses. "Considering that phenylbutazone and other NSAIDs are known to have important adverse effects in horses when used long-term and that these drugs are not able to alter the course of OA but only help control clinical signs, alternatives are needed," explained researcher David Frisbie, DVM, PhD, Dipl. ACVS. One such alternative is diclofenac liposomal cream--an NSAID that is applied to the skin overlying the affected joint(s) to control pain and inflammation of the tarsal, carpal, metacarpophalangeal, metatarsophalangeal and proximal interphalangeal joints. This product is approved by the Food and Drug Administration and is the first product of its kind manufactured for horses. Results of this study were presented at the 2007 annual American Association of Equine Practitioners' conference and were recently published in the study, "Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis," in the February edition of the American Journal of Veterinary Research.
    [Show full text]
  • Flunixin: a Vulture-Toxic Drug
    Flunixin: a vulture-toxic drug Summary of evidence that flunixin is toxic to vultures; and that meloxicam, an alternative to flunixin, is not toxic to vultures as well as a safe and effective veterinary drug Version 1: November 2016 SAVE is an international consortium of conservation and research organisations whose mission is to respond to the vulture crisis in Asia by striving to halt vulture population declines and working to minimise their negative impacts on ecological and human health. For further details go to www.save-vultures.org Flunixin: a vulture-toxic drug SAVE 11.2016 Flunixin is toxic to Gyps vultures; however, meloxicam is not toxic to Gyps vultures and an effective alternative to flunixin for veterinary purposes Aim This paper, intended for decision-makers involved in drug licensing, presents evidence of the toxicity of flunixin, a non-steroidal anti-inflammatory drug (NSAID), to Gyps vultures; and the safety, to both vultures and domesticated animals, and effectiveness, in domesticated animals, of meloxicam, an alternative NSAID. Executive summary 1. The NSAID flunixin has been found in dead wild Gyps vultures. 2. Wild vultures are exposed to NSAIDs when feeding on carcasses of domesticated ungulates treated with these drugs shortly before death. 3. Published and unpublished data from wildlife forensic investigations in Spain shows visceral gout (i.e., a clinical sign of renal failure in birds) and flunixin residue, but not diclofenac residue, in carcasses of three Eurasian griffon vultures Gyps fulvus. 4. Captive vultures are also exposed to NSAIDs through veterinary care. 5. A survey of wildlife veterinarians found the use of flunixin caused visceral gout and death in 2 out of 4 cases involving a captive Gyps vulture.
    [Show full text]
  • List Item Frequently Asked Questions on Phenylbutazone in Horsemeat
    15 April 2013 Frequently asked questions on Phenylbutazone in horsemeat 1. What is phenylbutazone? 2. What is the situation regarding phenylbutazone in food in the EU? 3. Why was phenylbutazone banned for use in food-producing animals? 4. What are the known toxic effects of phenylbutazone? 5. What is the likelihood of consumers being exposed to phenylbutazone in horsemeat? 6. What were EFSA and EMA asked to do by the European Commission? 7. What information did EFSA and EMA consider in their risk assessment of phenylbutazone? 8. What are the main conclusions of the joint statement? 9. What did the report conclude with regard to the potential risk for consumers? 10. What recommendations did EFSA and EMA make to further reduce the risk of phenylbutazone entering the food chain? 11. What is EFSA’s role with regards to the management of issues such as the contamination of beef products with horsemeat? 12. What is EMA’s contribution to this joint risk assessment regarding the public health implications of phenylbutazone in horsemeat? 1. What is phenylbutazone? Phenylbutazone – sometimes also referred to as “bute” – is a substance that falls into the class of drugs known as non steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are routinely used as painkillers in human and veterinary medicine. Phenylbutazone was introduced in 1949 as a human medicine for the treatment of rheumatoid arthritis and gout. These days it is used only under specialist supervision in patients who suffer from a severe form of arthritis where other treatments have not worked. Phenylbutazone is used for the treatment of pain and fever in horses and dogs.
    [Show full text]
  • STUDIES with NON-STEROIDAL ANTI-INFLAMMATORY DRUGS By
    STUDIES WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS by Elizabeth Ann Galbraith M.Sc., C.Biol., M.I.Biol. A thesis submitted for the degree of Doctor of Philosophy in the Faculty of Veterinary Medicine of the University of Glasgow Department of Veterinary Pharmacology M ay 1994 ProQuest Number: 11007888 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 11007888 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 4kh! TUT GLASGOW UNIVERSITY ) LIBRARY i To Ian ii TABLE OF CONTENTS Acknowledgements v Declaration vi Summary vii List of tables xi List of figures xv Abbreviations xvii Chapter 1 - General Introduction 1 Chapter 2 - General Material and Methods 29 Chapter 3 - Studies with Flunixin 3.1 Introduction 43 3.2 Experimental Objectives 44 3.3 Materials and Methods 45 3.4 Experiments with Flunixin 48 3.5 Results of Oral Experiments with Flunixin 49 3.6 Results of Intravenous Experiments with Flunixin 53 3.7 Results of Subcutaneous Experiments with Flunixin 55 3.8 Discussion 57 3.9 Tables and Figures
    [Show full text]
  • Original Paper Enhancement of Chemotherapeutic Drug Toxicity To
    European Journal of Cancer, Vol. 34, No. 8, pp. 1250±1259, 1998 # 1998 Elsevier Science Ltd. All rights reserved Pergamon Printed in Great Britain 0959-8049/98 $19.00+0.00 PII: S0959-8049(98)00045-8 Original Paper Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-steroidal Anti-in¯ammatory Drugs (NSAIDs) C.P. DuVy, C.J. Elliott, R.A. O'Connor, M.M. Heenan, S. Coyle, I.M. Cleary, K. Kavanagh, S. Verhaegen, C.M. O'Loughlin, R. NicAmhlaoibh and M. Clynes National Cell and Tissue Culture Centre, Dublin City University, Glasnevin, Dublin 9, Ireland The eVect on cytotoxicity of combining a range of clinically important non-steroidal anti-in¯amma- tory drugs (NSAIDs) with a variety of chemotherapeutic drugs was examined in the human lung cancer cell lines DLKP, A549, COR L23P and COR L23R and in a human leukaemia line HL60/ADR. A speci®c group of NSAIDs (indomethacin, sulindac, tolmetin, acemetacin, zomepirac and mefenamic acid) all at non-toxic levels, signi®cantly increased the cytotoxicity of the anthracyclines (doxorubicin, daunorubicin and epirubicin), as well as teniposide, VP-16 and vincristine, but not the other vinca alkaloids vinblastine and vinorelbine. Asubstantial number of other anticancer drugs, including methotrexate, 5-¯uorouracil, cytarabine, hydroxyurea, chlorambucil, cyclophosphamide, cisplatin, carboplatin, mitoxantrone, actinomycin D, bleomycin, paclitaxel and camptothecin, were also tested, but displayed no synergy in combination with the NSAIDs. The synergistic eVect was concentration dependent. The eVect appears to be independent of the cyclo-oxygenase inhibitory ability of the NSAIDs, as (i) the synergistic combination could not be reversed by the addition of prostaglandins D2 or E2; (ii) sulindac sulphone, a metabolite of sulindac that does not inhibit the cyclooxygenase enzyme, was positive in the combination assay: and (iii) many NSAIDs known to be cyclo-oxygenase inhibitors, e.g.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs: Pharmacokinetics and Mitigation of Procedural-Pain in Cattle
    animals Article Non-Steroidal Anti-Inflammatory Drugs: Pharmacokinetics and Mitigation of Procedural-Pain in Cattle Brooklyn K. Wagner 1 , Emma Nixon 1 , Ivelisse Robles 1, Ronald E. Baynes 1, Johann F. Coetzee 2 and Monique D. Pairis-Garcia 1,* 1 Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA; [email protected] (B.K.W.); [email protected] (E.N.); [email protected] (I.R.); [email protected] (R.E.B.) 2 Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA; [email protected] * Correspondence: [email protected] Simple Summary: Castration and disbudding, common husbandry procedures used in cattle live- stock production industries, are recognized as being painful. In the United States (U.S.), these procedures are frequently performed without pain relief. Although non-steroidal anti-inflammatory drugs (NSAIDs) are used in food-animal production systems, no such pain relief drugs are federally approved in the U.S. for controlling procedural pain in cattle to date. Recent increases in consumer, retailer and producer commitment to improving the welfare of food-animals necessitate a closer look into pain control efforts for livestock. Therefore, this review comprehensively evaluated existing literature to summarize three NSAIDs (meloxicam, flunixin and aspirin) (1) pharmacokinetics and (2) administration outcome in regard to pain control during castration and disbudding procedures, in cattle. The sample size contained notable variability and a general deficiency of validated and replicated methodologies for assessing pain in cattle represent on-going challenges. Future research Citation: Wagner, B.K.; Nixon, E.; should prioritize replication of pain assessment techniques across different experimental conditions Robles, I.; Baynes, R.E.; Coetzee, J.F.; to close knowledge gaps identified by the present study and facilitate examination of the effectiveness Pairis-Garcia, M.D.
    [Show full text]